SOM-230

Known as: SOM 230, SOM230 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pasireotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2010
Review
2010
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years. GEP… (More)
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Atypical femoral fractures and bisphosphonate use.
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cush1. ing’s syndrome. Lancet 2006;367:1605-17. de Bruin C, Pereira AM… (More)
Is this relevant?
2010
2010
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
CONTEXT Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms. Pituitary… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2010
2010
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2007
2007
Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages.
Somatostatin (SRIF)-14 is recognized as an important mediator between the nervous and the immune system, although the functional… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
OBJECTIVES Somatostatin (SST) analogues play an important role in the medical management of somatotroph pituitary adenomas and… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide… (More)
Is this relevant?
Review
2004
Review
2004
Future aspects of somatostatin-receptor-mediated therapy.
More than 30 years have passed since somatostatin was discovered and its hormonal function defined. The wide range of anatomical… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?